

Implanet commences trading on OTCQX in the U.S.

Level 1 American Depositary Receipts (ADRs) trade under the symbol IMPZY

Bordeaux, Boston, April 13, 2016: IMPLANET (Euronext: IMPL, FR0010458729, PEA-PME eligible; OTCQX: IMPZY), a medical technology company specializing in vertebral and knee-surgery implants, announces that its sponsored Level 1 American Depositary Receipts (ADRs) will commence trading today in the United States on OTCQX® (“OTCQX”), under the symbol IMPZY, with each ADR representing 2 ordinary shares on Euronext.

Implanet will continue to trade on EURONEXT under its existing ticker IMPL. OTCQX International is a tier of the OTCQX market reserved for high-quality non-U.S. companies that are listed on a qualified international exchange, meet high financial standards and provide their home country disclosure in English to U.S. investors. U.S. investors can find current financial disclosures and Real-Time Level 2 quotes for the Company at: www.otcm Markets.com/stock/IMPZY/quote.

David Dieumegard, CFO of Implanet commented: “Given our increased presence in the U.S. following the recent FDA clearance of our latest device to address the degenerative spine market, JAZZ Lock®, we are very pleased that our ADRs are now trading on the OTCQX market. OTCQX provides Implanet the opportunity to create a better informed and more efficient marketplace for U.S.-based investors. Joining OTCQX will complement our presence on EURONEXT, while facilitating and enhancing global trading in Implanet’s shares.”

“We are thrilled to welcome Implanet to our family of established, investor-focused U.S. and global companies,” said Jason Paltowitz, Executive Vice President of Corporate Services at OTC Markets Group. “Trading on OTCQX will allow Implanet to expand its shareholder base and visibility in the U.S. market without incurring the high cost and duplicative regulatory requirements of a U.S. stock exchange listing.” We look forward to being part of Implanet’s continued growth and success.

BNY Mellon serves as Implanet’s Principal American Liaison (“PAL”) on OTCQX, responsible for providing professional guidance on OTCQX requirements ([BNY Mellon](#)).

DISCLAIMER

This press release contains forward-looking statements, which are subject to risks and uncertainties. Actual results could differ materially from those forward looking statements.

Next financial press release: Q1 2016 revenue, on April 28, 2016



About IMPLANET

Founded in 2007, IMPLANET is a medical technology company that manufactures high-quality implants for orthopedic surgery. Its flagship product, the JAZZ latest-generation implant, aims to treat spinal pathologies requiring vertebral fusion surgery. Protected by four families of international patents, JAZZ has obtained 510(k) regulatory clearance from the Food and Drug Administration (FDA) in the United States and the CE mark. IMPLANET employs 48 people and recorded 2015 sales of €6.7 million. For further information, please visit www.implanet.com.

Based near Bordeaux in France, IMPLANET established a US subsidiary in Boston in 2013.
IMPLANET is listed on Compartment C of the Euronext™ regulated market in Paris.

Contacts

IMPLANET
Ludovic Lastennet
CEO
Tel.: +33 (5) 57 99 55 55
investors@implanet.com

Alpha Bronze
US – Investor Relations
Pascal Nigen
Tel.: +1 (917) 385-2160
implanet@alphabronze.net

NewCap
Investor Relations – France
Florent Alba
Tel.: +33 (5) 57 99 55 55
investors@implanet.com

NewCap
Media Relations
Nicolas Merigeau
Tel.: +33 (0)1 44 71 94 98
implanet@newcap.eu